Clinical Trials Browser

Withdrawn × brigatinib × Lymphoid × Clear all

NCT03719898 2021-01-05

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Phase 2 Withdrawn

Lymphoma, Large-Cell, Anaplastic

NCT04260009 2020-03-05

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Phase 1/2 Withdrawn

Lymphoma, Large-Cell, Anaplastic